Encapsulate Company Profile

Background

Encapsulate, founded in 2018 and headquartered in Farmington, Connecticut, is a biotechnology company specializing in precision diagnostics for personalized cancer therapy. The company has developed an automated tumor-on-a-chip system capable of growing patient-derived microtumors to screen them against various chemotherapeutic drugs. This technology aims to provide oncologists with evidence-driven insights into each patient's therapeutic response profile, facilitating the determination of the most effective clinical treatment regimen on a personalized basis.

Key Strategic Focus

Encapsulate's strategic focus centers on revolutionizing cancer treatment through personalized diagnostics. The company's core objectives include:

Automated Tumor-on-a-Chip Systems: Developing biochips that cultivate patient-derived microtumors to test the efficacy of chemotherapy drugs, thereby reducing unnecessary treatment cycles and associated costs.

Precision Diagnostics: Providing rapid, evidence-based insights to oncologists, enabling the selection of the most effective treatments and significantly improving patient outcomes.

Collaborations with Pharmaceutical Companies: Offering customized assays and resolving issues related to drug solubility, targeting, and stability. Utilizing a comprehensive patient biobank to facilitate pre-clinical trials, patient stratification, and in-depth mechanism studies.

Financials and Funding

Encapsulate has secured multiple funding rounds to support its innovative endeavors:

Seed Funding: In November 2024, the company closed an oversubscribed seed round, raising $1.8 million. This round was led by Blackwood Healthcare Breakthroughs, Ambit Health Ventures, and Connecticut Innovations.

Grants: Encapsulate has been awarded several grants, including a $3.63 million Phase 1 grant through NASA’s In Space Production Applications (InSPA) program in July 2025 to develop microgravity-enabled Metastasis-on-a-Chip technology. Additionally, in July 2025, the company received a $1.25 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation to advance its automated chemotherapy selection platform for pancreatic and colorectal cancers.

Pipeline Development

Encapsulate's pipeline includes:

nCapsule 3D System: A three-dimensional cell culture system that better mimics the in vivo microenvironment of tissues, allowing researchers to study cellular behavior, disease progression, and drug responses in a more physiologically relevant model.

Metastasis-on-a-Chip Technology: Under development with support from NASA’s InSPA program, this technology aims to utilize microgravity conditions to study cancer metastasis, potentially leading to new insights into cancer progression and treatment.

Technological Platform and Innovation

Encapsulate's proprietary technologies and methodologies include:

Automated Tumor-on-a-Chip Systems: These systems cultivate patient-derived microtumors to test the efficacy of chemotherapy drugs, providing personalized treatment insights.

nCapsule 3D System: This system offers a more accurate representation of the in vivo tumor microenvironment, enhancing the predictive value of preclinical studies.

High-Throughput Data Screening: Encapsulate's devices can investigate up to 120 tumoroids in parallel, facilitating efficient and comprehensive data collection.

Leadership Team

Encapsulate's leadership comprises experienced professionals dedicated to advancing personalized cancer therapy:

Armin Tahmasbi Rad, PhD: Co-founder and Chief Executive Officer. Dr. Rad has been instrumental in developing Encapsulate's core technologies and guiding the company's strategic direction.

Leila Daneshmandi, PhD: Co-founder and Chief Operating Officer. Dr. Daneshmandi has played a key role in operational management and business development.

Reza Amin, PhD: Co-founder and Advisor. Dr. Amin has contributed significantly to the technological innovations at Encapsulate.

Bret Schipper, MD, FACS: Chief Medical Officer. Dr. Schipper provides medical oversight and strategic guidance for clinical applications.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within Encapsulate's leadership team.

Competitor Profile

Market Insights and Dynamics

The oncology diagnostics market is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for personalized treatment options. Advances in biotechnology and precision medicine are propelling the development of innovative diagnostic tools.

Competitor Analysis

Encapsulate operates in a competitive landscape with several notable companies:

Kiyatec: Specializes in 3D cell culture technology to predict patient-specific responses to cancer therapies.

Known Medicine: Develops patient-derived organoid models to assess drug efficacy and guide personalized treatment plans.

Xilis: Focuses on microfluidic technology to create patient-specific tumor organoids for drug testing.

SageMedic: Utilizes ex vivo patient tumor samples to evaluate therapeutic responses and inform treatment decisions.

Strategic Collaborations and Partnerships

Encapsulate has established significant collaborations to enhance its market position and innovation capacity:

NASA: Partnered through the InSPA program to develop microgravity-enabled Metastasis-on-a-Chip technology.

National Science Foundation: Received SBIR Phase II funding to advance automated chemotherapy selection platforms.

Hartford HealthCare: Conducted pilot studies to validate the accuracy and efficacy of Encapsulate's tumor-on-a-chip technology.

Operational Insights

Encapsulate's strategic considerations include:

Technological Differentiation: Leveraging proprietary tumor-on-a-chip systems to offer personalized diagnostics that improve treatment outcomes.

Market Positioning: Focusing on precision diagnostics to address the unmet needs in personalized cancer therapy.

Competitive Advantages: Rapid turnaround times, high-throughput screening capabilities, and the ability to mimic the in vivo tumor microenvironment more accurately than traditional methods.

Strategic Opportunities and Future Directions

Encapsulate's strategic roadmap includes:

Expansion of Technological Platforms: Further development of the nCapsule 3D system and Metastasis-on-a-Chip technology to broaden applications in cancer diagnostics and treatment.

Clinical Validation: Conducting extensive clinical trials to validate the efficacy and reliability of its diagnostic platforms.

Market Expansion: Exploring partnerships with pharmaceutical companies and healthcare providers to integrate Encapsulate's technologies into standard oncology practices.